Similar articles

• Mortality risk among hemodialysis patients receiving different vitamin D analogs.

  Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc. Tentori F, et al. Kidney Int. 2006 Nov;70(10):1858-65. doi: 10.1038/sj.ki.5001868. Epub 2006 Oct 4. Kidney Int. 2006. PMID: 17021609
• Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.

  Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M. Brancaccio D, et al. J Nephrol. 2007 Jan-Feb;20(1):3-9. J Nephrol. 2007. PMID: 17347966 Review.
• Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.

  El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. El-Shafey EM, et al. Ther Apher Dial. 2011 Dec;15(6):547-55. doi: 10.1111/j.1744-9987.2011.00994.x. Ther Apher Dial. 2011. PMID: 22107691 Clinical Trial.
• 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.

  Brandi L. Brandi L. Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
• Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.

  Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB. Hernandez JD, et al. Nat Clin Pract Nephrol. 2007 Apr;3(4):227-32. doi: 10.1038/ncpneph0443. Nat Clin Pract Nephrol. 2007. PMID: 17389892